Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Q4 2024 Earnings Call Transcript February 28, 2025 Gem Hopkins: Good morning and good afternoon, everyone. Thank you for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback